Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 7/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250243 | 0.91 | HTR1B (0.71) | HTR1BKCNH2HTR1AHTR1DHTR2A | |
| SCHEMBL5309042 | 0.90 | HTR1B (0.79) | HTR1BKCNH2HTR1AHTR1DMEN1 | |
| SCHEMBL14529770 | 0.88 | HTR1B (0.66) | HTR1BKCNH2HTR1AHTR1DHTR2A | |
| SCHEMBL14530405 | 0.88 | HTR1B (0.60) | HTR1BKCNH2HTR1AHTR1DMEN1 | |
| SCHEMBL5308451 | 0.87 | HTR1B (0.78) | HTR1BKCNH2HTR1AHTR1DHTR2A | |
| SCHEMBL4246690 | 0.87 | HTR1B (0.62) | HTR1BKCNH2HTR1AHTR1DHTR2A | |
| SCHEMBL5309015 | 0.87 | HTR1B (0.65) | HTR1BKCNH2HTR1AHTR1DHTR2A | |
| SCHEMBL4247598 | 0.86 | HTR1B (0.65) | HTR1BKCNH2HTR1AHTR1DHTR2A | |
| SCHEMBL5311017 | 0.84 | HTR1B (0.66) | HTR1BKCNH2MEN1KMT2AMAPT | |
| SCHEMBL4597945 | 0.84 | HTR1B (0.66) | HTR1BKCNH2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | claimed |
| WO-2007053094-A1 | CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| WO-2007053094-A1 | CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053094-A1 | CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135442-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | HTR1B 592/4885KCNH2 1018/4885HTR1A 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.